2. Others Metabolic Enzyme/Protease Anti-infection
  3. Biochemical Assay Reagents Aminotransferases (Transaminases) Phosphatase Bacterial
  4. Dioctyl phthalate

Dioctyl phthalate  (Synonyms: DNOP; Di-n-octyl phthalate; Phthalic acid dioctyl ester)

Cat. No.: HY-W013755 Purity: 99.40%
COA
SDS
Handling Instructions Technical Support

Dioctyl phthalate (DNOP) is a plasticizer. Dioctyl phthalate increases the activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the liver, as well as the levels of creatinine and urea in the kidney. Exposure to Dioctyl phthalate disrupts the homeostasis of the intestinal microbial community, increases the abundance of pathogenic bacteria, and reduces the abundance of beneficial bacteria such as Lactobacillus. Dioctyl phthalate induces significant and dose-dependent inflammatory responses in the liver, spleen and kidney of mice.

For research use only. We do not sell to patients.

Dioctyl phthalate

Dioctyl phthalate Chemical Structure

CAS No. : 117-84-0

Size Price Stock Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Liquid
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Dioctyl phthalate:

Dioctyl phthalate Related Antibodies

Top Publications Citing Use of Products

View All Aminotransferases (Transaminases) Isoform Specific Products:

View All Isoforms
GPT/ALT GOT/AST

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dioctyl phthalate (DNOP) is a plasticizer. Dioctyl phthalate increases the activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the liver, as well as the levels of creatinine and urea in the kidney. Exposure to Dioctyl phthalate disrupts the homeostasis of the intestinal microbial community, increases the abundance of pathogenic bacteria, and reduces the abundance of beneficial bacteria such as Lactobacillus. Dioctyl phthalate induces significant and dose-dependent inflammatory responses in the liver, spleen and kidney of mice[1].

In Vivo

Dioctyl phthalate (50-500 mg/kg⋅bw; oral gavage; daily; 12 weeks) induces dose-dependent multi-organ damage (liver, spleen, kidney, ileum) and gut microbiota dysbiosis in young C57BL/6J male mice, with high-dose exposure causing significant increases in hepatic ALT (P < 0.01) and ALP (P < 0.001) levels, splenic weight (P < 0.05), renal creatinine (P < 0.05) levels, and reduced Firmicutes/Bacteroidetes ratio (P < 0.05).
Dioctyl phthalate (50-500 mg/kg⋅bw; oral gavage; daily; 12 weeks) induces multi-organ damage (liver, spleen, kidney, ileum) and gut microbiota dysbiosis in aged C57BL/6J male mice, with high-dose exposure causing significant weight loss (P < 0.05), increased liver-to-body weight ratio (P < 0.001), elevated hepatic ALT (P < 0.01) and ALP (P < 0.05) levels, increased splenic weight (P < 0.01), elevated renal creatinine (P < 0.05) levels, and reduced Firmicutes/Bacteroidetes ratio in low-dose mice (P < 0.05).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (4-week-old, male, 18-21 g, SPF-grade)[2]
Dosage: 50 mg/kg⋅bw; 500 mg/kg⋅bw
Administration: daily; 12 weeks
Result: Caused sluggishness, lethargy, and decreased vitality in high-dose mice.
Increased body weight compared to controls, with smaller increase in high-dose group than low-dose group (P < 0.01).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.01) groups compared to controls; increased liver-to-body weight ratio in a dose-dependent manner.
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.001) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.05) and spleen index (P < 0.01) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) levels in high-dose group compared to controls; significantly elevated urea levels (P < 0.05) in both dose groups compared to controls.
Significantly increased serum diamine oxidase (DAO) and D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (50.9% in controls, 44.3% in low-dose, 39% in high-dose) and increased Bacteroidetes abundance (24.8% in controls, 35.9% in low-dose, 38.4% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in high-dose group compared to controls (P < 0.05).
Animal Model: C57BL/6J (76-week-old, male, 29-40 g, SPF-grade)[2]
Dosage: 50 mg/kg⋅bw; 500 mg/kg⋅bw
Administration: daily; 12 weeks
Result: Caused sluggishness, lethargy, decreased vitality, and significant weight loss in high-dose mice compared to controls (P < 0.05).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.05) groups compared to controls; significantly increased liver-to-body weight ratio only in high-dose group (P < 0.001).
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.05) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.01) and spleen index (P < 0.001) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) and urea (P < 0.05) levels in high-dose group compared to controls.
Significantly increased serum diamine oxidase (DAO) levels in high-dose group compared to controls (P < 0.05); significantly increased D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (61.3% in controls, 36.8% in low-dose, 32.4% in high-dose) and increased Bacteroidetes abundance (28.6% in controls, 37.7% in low-dose, 43.9% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in low-dose group compared to controls (P < 0.05).
Molecular Weight

390.56

Formula

C24H38O4
CAS No.
Appearance

Liquid (Density: 0.978 g/cm3)

Color

Colorless to light yellow

SMILES

O=C(OCCCCCCCC)C1=CC=CC=C1C(OCCCCCCCC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (256.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5604 mL 12.8021 mL 25.6043 mL
5 mM 0.5121 mL 2.5604 mL 5.1209 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.40%

SDS (702 KB)

COA (246 KB) HNMR (267 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5604 mL 12.8021 mL 25.6043 mL 64.0107 mL
5 mM 0.5121 mL 2.5604 mL 5.1209 mL 12.8021 mL
10 mM 0.2560 mL 1.2802 mL 2.5604 mL 6.4011 mL
15 mM 0.1707 mL 0.8535 mL 1.7070 mL 4.2674 mL
20 mM 0.1280 mL 0.6401 mL 1.2802 mL 3.2005 mL
25 mM 0.1024 mL 0.5121 mL 1.0242 mL 2.5604 mL
30 mM 0.0853 mL 0.4267 mL 0.8535 mL 2.1337 mL
40 mM 0.0640 mL 0.3201 mL 0.6401 mL 1.6003 mL
50 mM 0.0512 mL 0.2560 mL 0.5121 mL 1.2802 mL
60 mM 0.0427 mL 0.2134 mL 0.4267 mL 1.0668 mL
80 mM 0.0320 mL 0.1600 mL 0.3201 mL 0.8001 mL
100 mM 0.0256 mL 0.1280 mL 0.2560 mL 0.6401 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dioctyl phthalate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dioctyl phthalate117-84-0DNOP Di-n-octyl phthalate Phthalic acid dioctyl esterBiochemical Assay ReagentsAminotransferases (Transaminases)PhosphataseBacterialinflammationC57BL/6J male micemouse livermouse kidneymouse spleenalanine aminotransferasealkaline phosphataseFirmicutes/Bacteroidetes ratiogut microbiotaileumInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dioctyl phthalate
Cat. No.:
HY-W013755
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (702 KB) Français - FR (702 KB) Deutsch - DE (702 KB) Norwegian - NO (702 KB) Español - ES (702 KB) Swedish - SV (702 KB) Italian - IT (702 KB) Korean - KR (702 KB) Portuguese - PT (702 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.